226 related articles for article (PubMed ID: 26847859)
1. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Yates DH
Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
[TBL] [Abstract][Full Text] [Related]
2. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
3. Lymphangioleiomyomatosis: New Treatment Perspectives.
Radzikowska E
Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
[TBL] [Abstract][Full Text] [Related]
4. Lymphangioleiomyomatosis.
Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
[TBL] [Abstract][Full Text] [Related]
5. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
6. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.
Courtwright AM; Goldberg HJ; Henske EP; El-Chemaly S
Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096282
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
8. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
[TBL] [Abstract][Full Text] [Related]
9. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
[TBL] [Abstract][Full Text] [Related]
10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
11. mTOR signaling in lymphangioleiomyomatosis.
Kristof AS
Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
[TBL] [Abstract][Full Text] [Related]
12. [Lymphangioleiomyomatosis].
Wirtz H
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
14. CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.
Evans JF; Obraztsova K; Lin SM; Krymskaya VP
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668092
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
16. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
Sadowski K; Kotulska K; Jóźwiak S
Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
[TBL] [Abstract][Full Text] [Related]
17. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
Goyer I; Dahdah N; Major P
Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N; Zhang T; Ji J; Xu KF; Tian X
Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.
Goldberg HJ; Harari S; Cottin V; Rosas IO; Peters E; Biswal S; Cheng Y; Khindri S; Kovarik JM; Ma S; McCormack FX; Henske EP
Eur Respir J; 2015 Sep; 46(3):783-94. PubMed ID: 26113676
[TBL] [Abstract][Full Text] [Related]
20. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
